Hers Telehealth: Specific Patient Profiles to Avoid and Who Should Look Elsewhere

Is Hers Legit? Regulatory Standing and What the Record Shows

Hers is operated by Hims & Hers Health, Inc., a publicly traded company (NYSE: HIMS). The platform is not a scam. Prescribers on the platform hold valid state licenses, and the company has maintained LegitScript certification, a third-party pharmacy verification program that cross-checks dispensing practices against state and federal standards.

FDA and Compounding Scrutiny

The legitimacy question gets more complicated around compounded GLP-1 medications. During the semaglutide shortage period, the FDA permitted 503A and 503B compounding pharmacies to produce semaglutide copies. The FDA officially declared the shortage resolved for Ozempic and Wegovy in February 2025 and issued guidance that compounded semaglutide must be discontinued by defined deadlines [1]. Hims & Hers publicly acknowledged in early 2025 that it would need to wind down its compounded semaglutide program in response to that FDA action [2].

That regulatory sequence matters for patients. Receiving a compounded GLP-1 from any telehealth platform, including Hers, during a period of regulatory uncertainty carries real risk: the product may not have FDA-approved bioequivalence data, and supply continuity is not guaranteed.

Complaint Patterns Worth Knowing

The Better Business Bureau (bbb.org) lists hundreds of complaints against Hims & Hers, the majority centering on subscription cancellation difficulty, unexpected charges, and delayed prescription fulfillment. These are operational complaints, not safety reports, but they reflect a business model built around recurring billing that can be hard to exit [3]. The FTC has issued broader guidance on negative-option marketing practices that apply directly to subscription telehealth companies [4].

Patient Profiles That Should Avoid Hers or Proceed With Caution

This section is the clinical core of the article. The profiles below are drawn from FDA prescribing information, published clinical guidelines, and the documented limitations of asynchronous telehealth care.

Profile 1: Women With a Personal or Family History of Hormone-Sensitive Cancers

Hers offers menopausal hormone therapy. Estrogen-containing HRT is contraindicated or requires specialist-level risk stratification in women with a personal history of breast cancer, endometrial cancer, or known BRCA1/BRCA2 mutations.

The 2022 Menopause Society (formerly NAMS) clinical practice statement specifies that systemic estrogen therapy for breast cancer survivors should only be considered after failure of non-hormonal therapies and "only in consultation with the patient's oncologist" [5]. An asynchronous intake form cannot replicate that consultation. Hers does screen for cancer history in its questionnaire, but the platform has no structural mechanism to ensure oncology sign-off before prescribing.

Women with dense breast tissue findings on recent mammography, a first-degree relative with premenopausal breast cancer, or any personal history of hormone-receptor-positive tumors should seek an in-person gynecologist or oncologist before starting HRT through any telehealth channel, Hers included.

Profile 2: Patients With Active or Unstable Cardiovascular Disease

GLP-1 receptor agonists such as semaglutide carry a boxed warning for thyroid C-cell tumors in rodents and require a complete cardiovascular history before prescribing. More directly, the SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with pre-existing cardiovascular disease and overweight or obesity, but that population received rigorous baseline cardiovascular workups and ongoing monitoring unavailable through asynchronous telehealth [6].

Women with uncontrolled hypertension (systolic <160 mmHg is a common telehealth eligibility threshold), recent MI within 12 months, unstable angina, or decompensated heart failure need cardiologist co-management, not a subscription app. HRT also carries venous thromboembolism risk: the Women's Health Initiative (N=16,608) found a hazard ratio of 2.06 for DVT with conjugated equine estrogen plus medroxyprogesterone acetate versus placebo [7]. Women with prior VTE, Factor V Leiden, or antiphospholipid syndrome should not start oral estrogen through any telehealth platform without hematology or specialist input.

Profile 3: Patients With Active Serious Mental Illness

Hers prescribes SSRIs, SNRIs, and other psychiatric medications following a questionnaire-based mental health intake. This is appropriate for mild-to-moderate depression and anxiety in patients with no psychotic history. The concern arises at the more severe end of the spectrum.

The FDA-approved prescribing information for sertraline, escitalopram, and related agents includes a black-box warning about increased suicidality in patients under age 25 during the first weeks of treatment [8]. Monitoring requirements in that window specify follow-up at one, two, four, and eight weeks after initiation, a schedule that is logistically difficult when care is delivered primarily through app messaging.

Patients with a diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, or any recent psychiatric hospitalization within the past 12 months should not receive psychiatric prescriptions via asynchronous telehealth. Starting an SSRI in unrecognized bipolar disorder can precipitate a manic episode. That clinical risk demands a structured diagnostic interview, not a questionnaire.

Profile 4: Adolescents and Patients Under Age 18

Hers markets to adults. Federal telehealth prescribing regulations and state minor-consent laws create a patchwork that the platform is not structured to manage safely. The FDA has not approved semaglutide (Wegovy) for patients with a BMI <27 kg/m2, and weight-loss medications in adolescents require pediatric endocrinology oversight per American Academy of Pediatrics 2023 guidelines [9]. Anyone under 18 should not use Hers for any service.

Profile 5: Women Who Are Pregnant or Actively Trying to Conceive

GLP-1 receptor agonists carry a Pregnancy Category X equivalent designation in current FDA labeling for Wegovy: semaglutide should be discontinued at least two months before a planned pregnancy [10]. HRT formulations containing progestogens are likewise contraindicated in pregnancy. Hers intake forms ask about pregnancy, but a D2C subscription model lacks the monitoring infrastructure to catch inadvertent conception during treatment.

Women actively trying to conceive, currently pregnant, or within two months postpartum should avoid Hers entirely and work with an OB-GYN or reproductive endocrinologist.

Profile 6: Patients Requiring Controlled Substances or Complex Polypharmacy Management

Hers does not prescribe scheduled controlled substances (benzodiazepines, stimulants, opioids). That is a responsible boundary. The issue surfaces in polypharmacy: women taking warfarin, narrow-therapeutic-index antiepileptics, lithium, or immunosuppressants may have drug-drug interactions with SSRIs or hormonal therapies that require pharmacist review and lab monitoring. A 2022 analysis in the Journal of the American Medical Association found that telehealth visits were significantly less likely to include medication reconciliation compared to in-person visits [11]. Women on five or more concurrent medications should have any new Hers prescription reviewed by their in-person prescriber or a clinical pharmacist before starting.

What Hers Does Reasonably Well

Fairness requires specificity. Hers performs adequately for a defined set of low-complexity cases.

Low-Risk Menopause Symptom Management

For healthy women aged 50 to 59 without cardiovascular risk factors seeking low-dose transdermal estradiol for vasomotor symptoms, the evidence base for telehealth-delivered HRT is reasonable. Transdermal estradiol avoids the first-pass hepatic metabolism associated with higher VTE risk seen with oral formulations [12]. Hers does offer transdermal options, and for the right patient the asynchronous model is a legitimate convenience.

Mild-to-Moderate Depression and Anxiety

The Collaborative Care Model evidence base supports stepped-care approaches to depression that begin with primary-care-level SSRI prescribing. STAR*D (N=2,876) showed that roughly 30% of patients achieve remission on their first SSRI trial [13]. For a woman with a PHQ-9 score in the mild-to-moderate range, no prior psychiatric hospitalization, and no bipolar features, a telehealth SSRI prescription with adequate follow-up messaging is clinically defensible.

Hair Loss in Otherwise Healthy Women

Minoxidil for female-pattern hair loss (androgenetic alopecia) has a well-established safety profile and FDA approval for topical use. The prescribing complexity is low, making it a reasonable telehealth offering [14].

The 5-Flag Checklist: A Decision Framework for Prospective Hers Patients

Before starting any Hers service, work through the five questions below. One "yes" answer warrants in-person specialist evaluation before proceeding. Two or more "yes" answers mean Hers is the wrong platform for your current clinical situation.

1. Cancer history flag. Do you have a personal or first-degree family history of breast, ovarian, or endometrial cancer, or a known BRCA mutation?
2. Cardiovascular flag. Have you had a blood clot, stroke, MI, or been told you have uncontrolled hypertension or a clotting disorder?
3. Psychiatric complexity flag. Have you ever been diagnosed with bipolar disorder, psychosis, or been hospitalized for a mental health reason?
4. Reproductive status flag. Are you pregnant, breastfeeding, or actively trying to conceive within the next two months?
5. Polypharmacy flag. Are you currently taking five or more prescription medications, including any narrow-therapeutic-index drug such as warfarin, lithium, or an antiepileptic?

This framework is intended as a starting point for conversation with a qualified clinician, not a substitute for one.

What Hers Complaints Reveal About Operational Risk

Beyond clinical safety, Hers complaints filed with the BBB and reflected in App Store reviews cluster around three operational failure modes that carry downstream health consequences.

Delayed or Interrupted Prescriptions

Multiple complainants report prescription delays of one to three weeks during high-demand periods. For mental health medications, abrupt discontinuation of an SSRI or SNRI can trigger discontinuation syndrome, characterized by dizziness, electric-shock sensations, and mood instability. The American Psychiatric Association's discontinuation guidance recommends tapering over a minimum of two to four weeks for most agents [15]. A fulfillment delay is not a taper.

Difficulty Reaching a Clinician for Urgent Questions

Asynchronous messaging platforms carry an inherent response-time lag. The American Telemedicine Association standards for asynchronous care recommend responses within 24 hours for non-urgent messages [16]. Adverse drug reactions, unexpected bleeding on HRT, or worsening depression do not reliably fall into a 24-hour window.

Subscription Billing Disputes

The FTC's Negative Option Rule (16 CFR Part 425) requires that subscription services provide simple cancellation mechanisms [4]. Hers complaints frequently describe difficulty canceling recurring charges after a patient has stopped using the service. While billing disputes are not a clinical harm, financial stress is a documented social determinant of health, and unexpected charges can create barriers to seeking care elsewhere.

How Hers Compares to In-Person Care: Key Structural Differences

| Feature | Hers (Telehealth) | In-Person Specialist | |---|---|---| | Physical exam | None | Available | | Lab ordering | Patient must arrange independently | Ordered and reviewed in-office | | Drug interaction review | Questionnaire-based | Full medication reconciliation | | Follow-up scheduling | App messaging, no guaranteed timeline | Structured follow-up appointments | | Specialist escalation | Patient self-refers | Direct referral pathway | | Controlled substances | Not prescribed | Available under appropriate monitoring |

What Regulators and Guidelines Actually Say About Telehealth Prescribing

The Ryan Haight Act (21 U.S.C. 829) historically required an in-person evaluation before a controlled substance could be prescribed via telemedicine. COVID-era DEA flexibilities extended telehealth prescribing for scheduled drugs, but those flexibilities have been subject to rolling deadline extensions, creating ongoing legal uncertainty for telehealth platforms [17].

For non-controlled substances, no federal law prohibits telehealth prescribing, but individual state medical boards retain authority over standard-of-care requirements. The Federation of State Medical Boards' telemedicine policy framework states that "the standard of care is not diminished solely because the care is delivered via telemedicine" [18]. That statement has teeth: a telehealth prescriber who skips indicated baseline labs (e.g., fasting glucose before prescribing semaglutide, or a mammogram review before starting estrogen) may fall below the standard of care regardless of the convenience model.

The American College of Obstetricians and Gynecologists supports telehealth for established OB-GYN patients but notes that new-patient visits for hormonal therapies benefit from an initial in-person evaluation when feasible [19].

"Physicians providing care via telemedicine must adhere to the same standards of practice as those providing in-person care," per the FSMB telemedicine policy, 2020 edition [18].

Alternatives to Consider Based on Your Profile

• Complex HRT needs. A board-certified menopause practitioner certified through the Menopause Society (formerly NAMS) is the appropriate starting point. The provider directory is available at menopause.org.
• GLP-1 weight loss with cardiovascular disease. An endocrinologist or obesity medicine specialist affiliated with the Obesity Medicine Association can coordinate cardiometabolic care.
• Psychiatric prescribing. Community mental health centers, university psychiatry departments, and psychiatry-trained primary care physicians provide the structured diagnostic evaluation that serious mental illness requires.
• Hair loss. A board-certified dermatologist can differentiate androgenetic alopecia from autoimmune alopecia areata, thyroid-related loss, or nutritional deficiency, distinctions a questionnaire cannot reliably make.